Search

Your search keyword '"Weidinger, Gerhard"' showing total 8 results
Start Over Author "Weidinger, Gerhard"
8 results on '"Weidinger, Gerhard"'

1. ELIMINATE: a PCR record-based macroelimination project for systematic recall of HCV-RNA-positive persons in Austria

Author

Schwarz, Caroline, Bauer, David, Dorn, Livia, Jachs, Mathias, Hartl, Lukas, Chromy, David, Weseslindtner, Lukas, Pfisterer, Nikolaus, Hennlich, Barbara, Stückler, Annika, Strassl, Robert, Voill-Glaninger, Astrid, Hübl, Wolfgang, Willheim, Martin, Köhrer, Karin, Jansen-Skoupy, Sonja, Tomez, Sabine, Krugluger, Walter, Madl, Christian, Schwarz, Michael, Balcar, Lorenz, Semmler, Georg, Brinkmann, Leonard, Burghart, Lukas, Antonitsch, Lukas, Weidinger, Gerhard, Riedl, Florian, Laferl, Hermann, Kurteva, Vesselina, Traugott, Marianna, Hind, Julian, Wenisch, Christoph, Aburaia, Abdelrahman, Sebesta, Christian, Schmid, Daniela, Rothweiler, Sonja, Remetic, Jelena, Gschwantler, Michael, Maieron, Andreas, and Reiberger, Thomas

Published
2024
Full Text
View/download PDF

3. ELIMINATE: a PCR record-based macroelimination project for systematic recall of HCV-RNA-positive persons in Austria

Author

Schwarz, Caroline, primary, Bauer, David, additional, Dorn, Livia, additional, Jachs, Mathias, additional, Hartl, Lukas, additional, Chromy, David, additional, Weseslindtner, Lukas, additional, Pfisterer, Nikolaus, additional, Hennlich, Barbara, additional, Stückler, Annika, additional, Strassl, Robert, additional, Voill-Glaninger, Astrid, additional, Hübl, Wolfgang, additional, Willheim, Martin, additional, Köhrer, Karin, additional, Jansen-Skoupy, Sonja, additional, Tomez, Sabine, additional, Krugluger, Walter, additional, Madl, Christian, additional, Schwarz, Michael, additional, Balcar, Lorenz, additional, Semmler, Georg, additional, Brinkmann, Leonard, additional, Burghart, Lukas, additional, Antonitsch, Lukas, additional, Weidinger, Gerhard, additional, Riedl, Florian, additional, Laferl, Hermann, additional, Kurteva, Vesselina, additional, Traugott, Marianna, additional, Hind, Julian, additional, Wenisch, Christoph, additional, Aburaia, Abdelrahman, additional, Sebesta, Christian, additional, Schmid, Daniela, additional, Rothweiler, Sonja, additional, Remetic, Jelena, additional, Gschwantler, Michael, additional, Maieron, Andreas, additional, and Reiberger, Thomas, additional

Published
2023
Full Text
View/download PDF

5. ELIMINATE-interim results of an Austrian HCV macro-elimination project

Author

Schwarz, Caroline, primary, Bauer, David Jm, additional, Dorn, Livia, additional, Jachs, Mathias, additional, Hartl, Lukas, additional, Holzmann, Heidemarie, additional, Pfisterer, Nikolaus, additional, Hennlich, Barbara, additional, Mayer, Florian, additional, Schmidt, Ralf, additional, Voll-Glaninger, Astrid, additional, Hübl, Wolfgang, additional, Willheim, Martin, additional, Köhrer, Karin, additional, Jansen-Skoupy, Sonja, additional, Tomez, Sabine, additional, Krugluger, Walter, additional, Madl, Christian, additional, Schwarz, Michael, additional, Brinkmann, Leonard, additional, Burghart, Lukas, additional, Weidinger, Gerhard, additional, Riedl, Florian, additional, Laferl, Hermann, additional, Wenisch, Christoph, additional, Aburaia, Abdelrahman, additional, Sebesta, Christian, additional, Schmid, Daniela, additional, Reiberger, Thomas, additional, Maieron, Andreas, additional, and Gschwantler, Michael, additional

Published
2022
Full Text
View/download PDF

7. Rituximab Maintenance Significantly Prolongs Event Free (EFS) and Progression Free Survival (PFS) In Male Patients With Aggressive B-Cell Lymphoma In The NHL13 Study

Author

Jaeger, Ulrich, Trneny, Marek, Melzer, Helen, Praxmarer, Michael, Fridrik, Michael A., Nawarawong, Weerasak, Ben Yehuda, Dina, Mihaljevic, Biljana, Ilhan, Osman, Ballova, Veronika, Hedenus, Michael, Hsiao, Liang-Tsai, Au, Wing-Yan, Thaler, Josef, Weidinger, Gerhard, Keil, Felix, Dittrich, Christian, Skrabs, Cathrin, Wolkersdorfer, Daniela, Klingler, Anton, Greil, Richard, and Goldstein, David

Abstract

Jaeger: Roche: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding. Off Label Use: Rituximab as maintenance treatment for DLBCL. Trneny:Roche: Honoraria, Research Funding. Fridrik:Roche: Honoraria. Hedenus:Vifor Pharma: Consultancy, Honoraria. Thaler:Roche: Honoraria, Research Funding. Keil:Roche: Honoraria. Dittrich:Roche: Honoraria, Research Funding. Greil:Roche: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding. Goldstein:Roche: Membership on an entity’s Board of Directors or advisory committees.

Published
2013
Full Text
View/download PDF

8. Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial.

Author

Jaeger U, Trneny M, Melzer H, Praxmarer M, Nawarawong W, Ben Yehuda D, Goldstein D, Mihaljevic B, Ilhan O, Ballova V, Hedenus M, Hsiao LT, Au WY, Burgstaller S, Weidinger G, Keil F, Dittrich C, Skrabs C, Klingler A, Chott A, Fridrik MA, and Greil R

Subjects
Adult, Aged, Aged, 80 and over, Female, Follow-Up Studies, Humans, Intention to Treat Analysis, Lymphoma, Follicular mortality, Lymphoma, Follicular pathology, Lymphoma, Large B-Cell, Diffuse mortality, Lymphoma, Large B-Cell, Diffuse pathology, Male, Middle Aged, Remission Induction, Sex Factors, Survival Analysis, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols, Lymphoma, Follicular drug therapy, Lymphoma, Large B-Cell, Diffuse drug therapy, Rituximab therapeutic use
Abstract

We investigated rituximab maintenance therapy in patients with diffuse large B-cell lymphoma (n=662) or follicular lymphoma grade 3b (n=21) in first complete remission. Patients were randomized to rituximab maintenance (n=338) or observation (n=345). At a median follow-up of 45 months, the event-free survival rate (the primary endpoint) at 3 years was 80.1% for rituximab maintenance versus 76.5% for observation. This difference was not statistically significant for the intent-to-treat population (likelihood ratio P=0.0670). The hazard ratio by treatment arm was 0.79 (95% confidence interval 0.57-1.08; P=0.1433). The secondary endpoint, progression-free survival was also not met for the whole statistical model (likelihood ratio P=0.3646). Of note, rituximab maintenance was superior to observation when treatment arms only were compared (hazard ratio: 0.62; 95% confidence interval 0.43-0.90; P=0.0120). Overall survival remained unchanged (92.0 versus 90.3%). In subgroup analysis male patients benefited from rituximab maintenance with regards to both event-free survival (84.1% versus 74.4%) (hazard ratio: 0.58; 95% confidence interval 0.36-0.94; P=0.0267) and progression-free survival (89.0% versus 77.6%) (hazard ratio: 0.45; 95% confidence interval 0.25-0.79; P=0.0058). Women had more grade 3/4 adverse events (P=0.0297) and infections (P=0.0341). Men with a low International Prognostic Index treated with rituximab had the best outcome. In summary, rituximab maintenance in first remission after R-CHOP-like treatment did not prolong event-free, progression-free or overall survival of patients with aggressive B-non-Hodgkin lymphoma. The significantly better outcome of men warrants further studies prior to the routine use of rituximab maintenance in men with low International Prognostic Index. This trial is registered under EUDRACT #2005-005187-90 and www.clinicaltrials.gov as #NCT00400478., (Copyright© Ferrata Storti Foundation.)

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results